Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: June 6, 2002
Last updated: July 17, 2013
Last verified: March 2003

RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells.

PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-small cell lung cancer, or breast cancer that has not responded to previous treatment.

Condition Intervention Phase
Breast Cancer
Kidney Cancer
Lung Cancer
Biological: interleukin-4 PE38KDEL cytotoxin
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: January 2002
Study Completion Date: July 2008
Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated dose of interleukin-4 PE38KDEL cytotoxin in patients with recurrent or unresponsive, metastatic renal cell, non-small cell lung, or breast cancer that overexpresses interleukin-4 receptors.
  • Determine the qualitative and quantitative toxic effects of this drug, including the duration and intensity of these toxic effects, in these patients.
  • Determine the pharmacokinetic behavior of this drug in these patients.
  • Determine the antibody response (if any) in patients treated with this drug.
  • Determine, in a preliminary manner, the antitumor activity of this drug in these patients.

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive interleukin-4 PE38KDEL cytotoxin (NBI-3001) IV over 10 minutes once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity, or detection of neutralizing antibodies.

Cohorts of 3-6 patients receive escalating doses of NBI-3001 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: A maximum of 36 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed recurrent or unresponsive, metastatic renal cell, non-small cell lung, or breast cancer that has been treated previously with standard surgery, radiotherapy, chemotherapy, or immunotherapy or for which no available treatment options currently exist
  • Confirmed overexpression of interleukin-4 receptors
  • Measurable disease (lesions greater than 10 mm by CT scan) OR
  • Evaluable disease
  • No prior or concurrent clinically significant brain metastases
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Male or female

Menopausal status:

  • Not specified

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • More than 12 weeks


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • Transaminases no greater than 1.5 times ULN
  • Albumin at least 2.5 g/dL
  • Hepatitis B surface antigen negative
  • Hepatitis C antibody negative
  • No prior or concurrent hepatic disease (e.g., hepatitis or alcoholic liver disease)


  • Creatinine no greater than 2.0 mg/dL


  • See Surgery
  • Electrocardiogram normal
  • MUGA scan normal
  • No congestive heart failure
  • No cardiac arrhythmia requiring treatment
  • No myocardial infarction
  • No clinical evidence of coronary artery disease (unless there is a cardiac evaluation and evidence of adequate coronary function by a stress test or angiography)


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception for 4 weeks before, during, and for at least 3 months after study
  • No concurrent underlying medical condition that would preclude study or cannot be controlled
  • No active infection


Biologic therapy:

  • See Disease Characteristics


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

Endocrine therapy:

  • Not specified


  • See Disease Characteristics
  • At least 4 weeks since prior radiotherapy


  • See Disease Characteristics
  • At least 1 year since prior surgery or angioplasty for coronary artery disease


  • At least 28 days since prior experimental drugs and recovered
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00039052

United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-5907
Sponsors and Collaborators
Neurocrine Biosciences
Study Chair: Henry Pan, MD, PhD Neurocrine Biosciences
  More Information

Additional Information:
No publications provided Identifier: NCT00039052     History of Changes
Other Study ID Numbers: NBI-3001-ST-0101  CDR0000069228  UARIZ-HSC-01196  UCLA-0108085  NCI-V02-1692 
Study First Received: June 6, 2002
Last Updated: July 17, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV breast cancer
recurrent breast cancer
recurrent non-small cell lung cancer
stage IV renal cell cancer
recurrent renal cell cancer
stage IV non-small cell lung cancer
male breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Kidney Neoplasms
Lung Neoplasms
Breast Diseases
Bronchial Neoplasms
Carcinoma, Bronchogenic
Kidney Diseases
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Adjuvants, Immunologic
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs processed this record on February 09, 2016